Anavex Life Sciences
AVXL
136 hedge funds and large institutions have $370M invested in Anavex Life Sciences in 2021 Q3 according to their latest regulatory filings, with 28 funds opening new positions, 46 increasing their positions, 29 reducing their positions, and 17 closing their positions.
65% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 17
59% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 29
7% more funds holding
Funds holding: 127 → 136 (+9)
5% more call options, than puts
Call options by funds: $19M | Put options by funds: $18.2M
2.64% less ownership
Funds ownership: 29.86% → 27.22% (-2.6%)
25% less capital invested
Capital invested by funds: $495M → $370M (-$125M)
Top Buyers
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.83M |
| 2 |
Charles Schwab
San Francisco,
California
|
+$6.77M |
| 3 |
PC
Pier Capital
Stamford,
Connecticut
|
+$5.5M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$3.44M |
| 5 |
Nomura Holdings
Tokyo,
Japan
|
+$2.99M |
Top Sellers
| 1 |
GLA
Great Lakes Advisors
Chicago,
Illinois
|
-$15.5M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$11.2M |
| 3 |
First Trust Advisors
Wheaton,
Illinois
|
-$4.07M |
| 4 |
EI
EAM Investors
Solana Beach,
California
|
-$4.06M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$3.86M |
AVXL Hedge Fund Activity: Q3 2021 in Review
136 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Anavex Life Sciences (AVXL) for Q3 2021, worth a combined $370M — down 25% from $495M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new AVXL positions and 17 closed out — a net gain of 11 holders — while 46 added to existing stakes and 29 trimmed.
The largest buyer was Vanguard Group, adding an estimated $6.83M. The largest seller was Great Lakes Advisors, exiting entirely with an estimated $15.5M sold.
- 136 institutional investors held Anavex Life Sciences (AVXL) as of Q3 2021, up from 127 in Q2 2021.
- Funds reported $370M of Anavex Life Sciences stock for Q3 2021, down 25% quarter-over-quarter.
- 28 funds opened new Anavex Life Sciences positions in Q3 2021 and 17 closed out, a net change of +11 holders.
- The largest Anavex Life Sciences buyer in Q3 2021 was Vanguard Group, an estimated $6.83M added.
- The largest Anavex Life Sciences seller in Q3 2021 was Great Lakes Advisors, an estimated $15.5M sold.
Based on aggregated 13F filings for Q3 2021.